Glipizide: adverse event reports filed with FDA

6,616

reports as suspect product

0% of all reports · about 294 a year

214

reports, 12 months to June 2026

209 in the 12 months before

58.7%

marked serious by the reporter

70.9% across the class

14.1%

record death among outcomes, as reported

932 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Glipizide reports recording the termmedian drug in sulfonylurea

1. Blood glucose increasedraised blood sugar reading15.8%1,043
2. Hypoglycaemialow blood sugar12.5%827
3. Drug ineffectivethe medicine did not work as expected10.4%691
4. Completed suicidedeath by suicide8.6%569
5. Blood glucose decreasedlow blood sugar reading7.5%494
6. Drug hypersensitivityan allergic-type reaction to a medicine3.9%257
7. Diarrhoealoose or frequent stools3.8%254
8. Nauseafeeling sick3.6%239
9. Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure3.5%232
10. Dizzinesslight-headedness or unsteadiness3.5%231
11. Toxicity to various agentspoisoning or toxic effect of one or more substances3.5%231
12. Drug interactionan interaction between medicines3.1%202
13. Diabetes mellitus inadequate controldiabetes not well controlled2.4%159
14. Malaisegeneral feeling of being unwell2.4%159
15. Weight decreasedweight loss2.4%158
16. Weight increasedweight gain2.4%156
17. Fatiguetiredness2.3%155
18. Astheniaweakness or lack of energy2.3%150
19. Headachehead pain2.1%136
20. Falla fall2%133
21. Blood glucose fluctuation2%132
22. Vomitingbeing sick2%131
23. Deaththe patient died; cause not stated by this term1.8%118
24. Dyspnoeashortness of breath1.8%116
25. Tremorshaking1.6%104
26. Acute kidney injurysudden loss of kidney function1.5%100
27. Blood glucose abnormal1.5%97
28. Confusional stateconfusion1.4%94
29. Decreased appetitereduced appetite1.4%94
30. Myocardial infarctionheart attack1.3%87

Top 30 of 720 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 4 drugs in the sulfonylurea class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 15,194 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 90.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 6,616 reports.

Drugs most often listed in the same reports

Other products listed in reports where Glipizide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the sulfonylurea class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Glipizide as a suspect or interacting product; reports listing it only as a concomitant medication (54,066) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.